These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 10859040)

  • 1. Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial. GAIN International Investigators.
    Lees KR; Asplund K; Carolei A; Davis SM; Diener HC; Kaste M; Orgogozo JM; Whitehead J
    Lancet; 2000 Jun; 355(9219):1949-54. PubMed ID: 10859040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycine antagonist in neuroprotection for patients with acute stroke: GAIN Americas: a randomized controlled trial.
    Sacco RL; DeRosa JT; Haley EC; Levin B; Ordronneau P; Phillips SJ; Rundek T; Snipes RG; Thompson JL;
    JAMA; 2001 Apr; 285(13):1719-28. PubMed ID: 11277826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of the Glycine Antagonist Gavestinel on cerebral infarcts in acute stroke patients, a randomized placebo-controlled trial: The GAIN MRI Substudy.
    Warach S; Kaufman D; Chiu D; Devlin T; Luby M; Rashid A; Clayton L; Kaste M; Lees KR; Sacco R; Fisher M;
    Cerebrovasc Dis; 2006; 21(1-2):106-11. PubMed ID: 16340185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gavestinel does not improve outcome after acute intracerebral hemorrhage: an analysis from the GAIN International and GAIN Americas studies.
    Haley EC; Thompson JL; Levin B; Davis S; Lees KR; Pittman JG; DeRosa JT; Ordronneau P; Brown DL; Sacco RL;
    Stroke; 2005 May; 36(5):1006-10. PubMed ID: 15831831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycine antagonist (GV150526) in acute stroke: a multicentre, double-blind placebo-controlled phase II trial.
    Lees KR; Lavelle JF; Cunha L; Diener HC; Sanders EA; Tack P; Wester P;
    Cerebrovasc Dis; 2001; 11(1):20-9. PubMed ID: 11173790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of blood pressure during the acute period of ischemic stroke on stroke outcome: a tertiary analysis of the GAIN International Trial.
    Aslanyan S; Fazekas F; Weir CJ; Horner S; Lees KR;
    Stroke; 2003 Oct; 34(10):2420-5. PubMed ID: 14500934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II studies of the glycine antagonist GV150526 in acute stroke : the North American experience. The North American Glycine Antagonist in Neuroprotection (GAIN) Investigators.
    Stroke; 2000 Feb; 31(2):358-65. PubMed ID: 10657406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of a glycine site antagonist (gavestinel) following multiple dosing in patients with acute stroke.
    Hoke JF; Dyker AG; Barnaby RJ; Lees KR
    Eur J Clin Pharmacol; 2000; 55(11-12):867-72. PubMed ID: 10805066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of natalizumab in patients with acute ischaemic stroke (ACTION): a randomised, placebo-controlled, double-blind phase 2 trial.
    Elkins J; Veltkamp R; Montaner J; Johnston SC; Singhal AB; Becker K; Lansberg MG; Tang W; Chang I; Muralidharan K; Gheuens S; Mehta L; Elkind MSV
    Lancet Neurol; 2017 Mar; 16(3):217-226. PubMed ID: 28229893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroprotective effects of glycine for therapy of acute ischaemic stroke.
    Gusev EI; Skvortsova VI; Dambinova SA; Raevskiy KS; Alekseev AA; Bashkatova VG; Kovalenko AV; Kudrin VS; Yakovleva EV
    Cerebrovasc Dis; 2000; 10(1):49-60. PubMed ID: 10629347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of uric acid in patients with acute stroke (URICO-ICTUS): a randomised, double-blind phase 2b/3 trial.
    Chamorro A; Amaro S; Castellanos M; Segura T; Arenillas J; Martí-Fábregas J; Gállego J; Krupinski J; Gomis M; Cánovas D; Carné X; Deulofeu R; Román LS; Oleaga L; Torres F; Planas AM;
    Lancet Neurol; 2014 May; 13(5):453-60. PubMed ID: 24703208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health care resource use after acute stroke in the Glycine Antagonist in Neuroprotection (GAIN) Americas trial.
    Rundek T; Nielsen K; Phillips S; Johnston KC; Hux M; Watson D;
    Stroke; 2004 Jun; 35(6):1368-74. PubMed ID: 15118182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health care resource use and stroke outcome. Multinational comparisons within the GAIN International trial.
    Asplund K; Ashburner S; Cargill K; Hux M; Lees K; Drummond M;
    Int J Technol Assess Health Care; 2003; 19(2):267-77. PubMed ID: 12862185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of desmoteplase given 3-9 h after ischaemic stroke in patients with occlusion or high-grade stenosis in major cerebral arteries (DIAS-3): a double-blind, randomised, placebo-controlled phase 3 trial.
    Albers GW; von Kummer R; Truelsen T; Jensen JK; Ravn GM; Grønning BA; Chabriat H; Chang KC; Davalos AE; Ford GA; Grotta J; Kaste M; Schwamm LH; Shuaib A;
    Lancet Neurol; 2015 Jun; 14(6):575-84. PubMed ID: 25937443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Excitatory amino acid antagonists for acute stroke.
    Muir KW; Lees KR
    Cochrane Database Syst Rev; 2003; 2003(3):CD001244. PubMed ID: 12917902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poststroke neurological improvement within 7 days is associated with subsequent deterioration.
    Aslanyan S; Weir CJ; Johnston SC; Lees KR;
    Stroke; 2004 Sep; 35(9):2165-70. PubMed ID: 15243144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial.
    Bluhmki E; Chamorro A; Dávalos A; Machnig T; Sauce C; Wahlgren N; Wardlaw J; Hacke W
    Lancet Neurol; 2009 Dec; 8(12):1095-102. PubMed ID: 19850525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and tolerability of GV150526 (a glycine site antagonist at the N-methyl-D-aspartate receptor) in patients with acute stroke.
    Dyker AG; Lees KR
    Stroke; 1999 May; 30(5):986-92. PubMed ID: 10229732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multinational randomised controlled trial of lubeluzole in acute ischaemic stroke. European and Australian Lubeluzole Ischaemic Stroke Study Group.
    Diener HC
    Cerebrovasc Dis; 1998; 8(3):172-81. PubMed ID: 9619701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of acute ischaemic stroke with the low-affinity, use-dependent NMDA antagonist AR-R15896AR. A safety and tolerability study.
    Diener HC; AlKhedr A; Busse O; Hacke W; Zingmark PH; Jonsson N; Basun H;
    J Neurol; 2002 May; 249(5):561-8. PubMed ID: 12021946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.